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ABSTRACT 
Background: Bronchodilators used to treat Chronic Obstructive Pulmonary disease 
have been associated with adverse cardiovascular events. Moreover, the high 
prevalence of cardiovascular diseases (CVD) in COPD (8-40%) requires an evaluation 
of treatment differences between comorbid groups in order to understand the 
appropriateness of drug prescribing. 
Objective: To determine whether COPD patients with concurrent CVD are less likely 
to be prescribed bronchodilators compared to those without CVD. 
Methods: A retrospective cross-sectional study was conducted using the 2010 
National Ambulatory Medical Care Survey (NAMCS) to quantify the association 
between concurrent CVD morbidity and the probability of receiving a bronchodilator 
prescription. Visits included patients ≥40 years who had COPD diagnosis. Survey-
weighted data were analyzed through descriptive analysis, univariate (unadjusted) and 
multivariate (adjusted) logistic regression models. Demographics, patient, physician 
and visit characteristics were assessed as covariates in the models. 
Results: Out of 11,627,061 ambulatory visits recorded by patients ≥40 years with 
COPD diagnosis, majority was male (57%), non-Hispanic White (80%) and used at 
least one bronchodilator (55.5%). We found that a significantly lower proportion of 
the COPD-CVD group (32.3%) was treated with bronchodilators versus 57.6% for the 
non-comorbid group. The effect of CVD on bronchodilator prescribing was modified 
by gender, beta-blockers and asthma. CVD patients who were female, not prescribed 
beta-blockers and not having concomitant asthma were 94% less likely to be 
prescribed bronchodilators compared the non-CVD females with the same 
  
characteristics. On the other hand, males not prescribed beta-blockers and not having 
concomitant asthma had 68% lower probability when CVD coexisted with COPD. 
Female CVD patients prescribed beta-blockers and not living with asthma had only a 
20% chance of being a bronchodilator user than those without CVD.  Cardiovascular 
disease did not affect the utilization of bronchodilators in males taking beta-blockers 
who either had or did not have asthma. 
Conclusion: Concurrent CVD diagnosis is a significant factor for reducing the 
probability of prescribing bronchodilators for COPD and our findings provide 
evidence of variations in bronchodilator prescribing for stratified groups of COPD-
CVD patients. Most patients with COPD and CVD are less likely to be prescribed 
bronchodilators, with the exception of males who were also prescribed beta-blockers.  
Thus, this study highlights a specific patient subgroup for whom the guidelines are  
less likely to be observed.
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CHAPTER 1 
 
INTRODUCTION 
 
Chronic Obstructive Pulmonary Disease (COPD) is defined as a “preventable and 
treatable disease characterized by persistent airflow limitation that is usually 
progressive and associated with an abnormal inflammatory response of the lung to 
noxious particles or gases. Exacerbations and comorbidities contribute to the overall 
severity in individual patients.”1  The disease is clinically diagnosed as one or more of 
3 subtypes – chronic bronchitis, emphysema and chronic airway obstruction.2    
COPD is the fourth leading cause of chronic morbidity and mortality in the 
United States affecting 6.5% of adults (13.7 million diagnosed cases) and leading to 
133,575 deaths.2 In 2010, there were 10.3 million physician office visits, 1.5 million 
emergency department visits, and 699,000 hospital discharges for COPD.2  Globally, 
COPD ranked fifth cause of years lived with disability (YLDs) in the 2010 global 
burden of disease study.3  The World Health Organization predicts that COPD will 
become the third leading cause of death worldwide by 2030.4  Inevitably, COPD is 
and will continue to be a major global health problem.5 
Bronchodilators are the mainstay for symptomatic treatment of COPD due to their 
ability to relieve bronchial obstruction and airflow limitation, improve emptying of the 
lungs and reduce hyperinflation during rest and exercise.6,7 Three major classes are 
recommended as first-line agents - beta-(β) 2-agonists, anticholinergics (AC), and 
methylxanthines, used alone or in combination or as single or combination drugs.7 
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Despite the benefits of bronchodilator agents in the treatment of COPD, patients 
may be at an increased risk of cardiovascular (CV) toxicity due to beta-adrenergic 
stimulation. Previous studies showing an association between bronchodilators and 
adverse cardiovascular events such as arrhythmias, myocardial ischemia, heart failure 
and sudden cardiac death, will be discussed in detail in the literature review section.8-13  
The potential cardiovascular risk of bronchodilators in COPD has important 
therapeutic implications for two main reasons: First of all, the prevalence of 
cardiovascular-related diseases (CVD) in COPD is estimated to range from 8% to as 
high as 40%1,14-16 making it the most frequent and most important disease group 
coexisting with COPD. Secondly, the exclusion of comorbid subjects from clinical 
trials often limits the use of trial data in providing practical treatment 
recommendations for the real world COPD patient population where multiple 
morbidities are highly prevalent.  
We hypothesize that cardiac disorders play an independent role in the lesser 
probability of receiving a bronchodilator prescription for COPD.  The objective of this 
study is to provide descriptive data on the classes of bronchodilator medications 
prescribed to ambulatory patients with diagnosed COPD in the United States and 
examine whether COPD patients with CVD are less likely to be prescribed 
bronchodilators compared to COPD patients without CVD. 
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CHAPTER 2 
 
REVIEW OF LITERATURE 
 
Etiology and Epidemiology of COPD and its Comorbidities 
Cigarette smoking is the dominant and best-studied risk factor for COPD, though 
a substantial burden of disease occurs in nonsmokers.17-19 Other etiologic factors such 
as advanced age, occupational exposure to dust, fumes and gases, indoor and outdoor 
air pollution, airway hyper-responsiveness, asthma, infections and genetic 
predisposition (α-antitrypsin deficiency) are also important.1 Furthermore, it has been 
increasingly recognized that COPD is more than just a lung disease: it is a complex 
heterogeneous systemic disease, frequently associated with other chronic diseases 
including coronary heart disease, cardiovascular, respiratory tract, metabolic, 
hematological, musculoskeletal, gastrointestinal, renal diseases, psychiatric disorders 
and neoplasias.14,15,20-23  
The prevalence of comorbidity in COPD has been studied using nationally-
representative data, National Health and Nutrition Examination Survey (NHANES) 
1999-2008.24 Using a ten-year analytic sample of 14,828 subjects (995 COPD cases) 
aged ≥45, subjects with self-reported physician diagnosis of COPD were more likely 
than subjects without physician-diagnosed COPD to have coexisting arthritis (54.6% 
vs. 36.9%), depression (20.6% vs. 12.5%), osteoporosis (16.9% vs. 8.5%), cancer 
(16.5% vs. 9.9%), coronary heart disease (12.7% vs. 6.1%), congestive heart failure 
(12.1% vs. 3.9%), and stroke (8.9% vs. 4.6%).24 
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Vanfleteren and colleagues used a cluster analysis approach to assess the 
prevalence and severity of objectively identified chronic concomitant disorders in a 
cohort of 213 patients with moderate to very severe COPD.25  The CIRO CO-
morbidity (CIROCO) study was an observational single-center study and almost all 
subjects (97.7%) had one or more comorbidities. More than half (53.5%) of the 
patients had at least four comorbidities. 
Another study in a sample of COPD patients referred to an Australian outpatient 
hospital-based pulmonary rehabilitation program reported that 96% of patients had at 
least 1 other chronic conditions and 29% had 5 or more comorbidities.26  Data were 
available on 70 patients and 64% of patients had multiple morbidities associated with 
cardiovascular disease.  
While it is likely that the prevalence of comorbidities in people with COPD is 
influenced by common risk factors, such as smoking, advanced age, chronic systemic 
inflammation, physical inactivity and low socioeconomic status, studies have 
confirmed that concurrent conditions worsen health outcomes independent of pre-
existing risk factors.26  Comorbidities in COPD lead to lower health-related quality of 
life,27,28 more hospitalizations, severe disabilities5 and higher rates of mortality29,30 
compared to those without comorbidities. 
 
Burden of comorbid COPD and Cardiovascular disease (CVD) 
Observational studies indicate that COPD is associated with a high prevalence of 
coronary artery disease, cardiac arrhythmias, cerebrovascular disease, peripheral 
vascular disease and congestive heart failure.31-33 In addition, COPD patients with 
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CVD pose significantly higher clinical and economic burden on patients and 
healthcare system than COPD patients without CVD.  
One large retrospective cross-sectional survey involving 618,090 subjects 
quantified the association between COPD and diagnosis of CVD and stroke and 
revealed that COPD was associated with a fivefold increase in the odds of having had 
CVD (OR 4.98, 95% CI 4.85 to 5.81; p<0.001), and a threefold increase in the odds of 
having had a stroke (OR 3.34, 95% CI 3.21 to 3.48; p <0.001).34     
Curkendall and colleagues found that the prevalence of all cardiovascular 
diseases was higher in the COPD group than in the comparison group 
subjects(n=11,493) in a retrospective cohort study in Saskatchewan longitudinal health 
care databases in Canada.35  After adjusting for cardiovascular risk, odds ratios of 
prevalence were: arrhythmia 1.76 (CI: 1.64–1.89), angina 1.61 (CI: 1.47–1.76), acute 
myocardial infarction 1.61 (CI: 1.43–1.81), congestive heart failure 3.84 (CI: 3.56–
4.14), stroke 1.11 (CI: 1.02–1.21), pulmonary embolism 5.46 (CI: 4.25–7.02). COPD 
patients also had an elevated risk of hospitalization and death (OR 2.7 CI: 1.82–2.36) 
due to cardiovascular causes.35  One limitation of the study was the lack of baseline 
smoking data which made it difficult to separate the cardiovascular effects of smoking, 
a major risk factor for both COPD and CVD, from the effects of COPD. 
Similar results on the impact of comorbid COPD-CVD on healthcare utilization 
were obtained in a retrospective matched-cohort of 4594 patients each with COPD and 
CVD ≥ 40 years of age using administrative claims data and propensity score 
technique for matching.36 The data source for this study was the IMS Lifelink 
Database containing medical and pharmacy claims data from over 100 different 
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managed healthcare plans (encompassing over 60 million patients) in the United 
States. The COPD-CVD cohort was about twice as likely than the COPD-only cohort 
to require COPD-related hospitalization (OR 1.95; p < 0.001), 47% more likely to 
have an ER visit (OR 1.47; p < 0.001) and 62% more likely to require hospitalization 
and/or ER visit (OR, 1.62; p <0.001).36  Significant differences in healthcare costs 
were found as the average annual all-cause medical costs per patient were $22,755 vs 
$8,036 (p<0.001), and total costs were $27,032 vs $11,506 (p<0.001), for COPD-CVD 
and for COPD-only groups respectively.36 Corresponding average COPD-related 
annual medical costs were $1891 vs $1060 (p<0.001) and total costs were $3295 vs 
$2379 (p < 0.001). 
 
COPD Treatment 
The most widely applied guideline for treatment is the Global Strategy for the 
Diagnosis, Management, and Prevention of COPD (GOLD strategy), revised in 2014 
containing summaries of current evidence on management and prevention strategies.1  
Four grades of disease are defined according to severity of airflow obstruction; mild 
disease A (FEV1 ≥80% predicted), moderate disease B (50% ≤ FEV1 <80% 
predicted), C severe disease (30% ≤ FEV1 <50%), and very severe disease D (FEV1 
<30% predicted); and the result of this classification leads to treatment choice. 
Pharmacotherapy constitutes the major intervention used in COPD patients. 
Medications commonly used for COPD are bronchodilators, corticosteroids and 
phosphodiesterase-4 inhibitors.37 None of the existing medications have been proven 
to change long-term decline in lung function, as such, the main goal of 
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pharmacological therapy is to reduce symptoms, decrease the frequency and severity 
of exacerbations, improve quality of life and exercise tolerance.1 
Non-pharmacological treatment modalities include pulmonary rehabilitation, 
oxygen therapy, ventilation support and surgical treatments.1 Regardless of disease 
stage, the identification and reduction of risk factors are important in COPD 
prevention and treatment. Smoking cessation is the first and most crucial step in 
COPD therapy for all COPD patients who smoke, and has greatly influenced the 
natural history of COPD and lowered mortality with long-term quit rates as high as 
25%.1  Use of smoking cessation products (Bupropion, Varenicline and Nortriptyline) 
combined with behavioral support is reported to increase successful smoking cessation 
compared with either intervention alone.1,37  
 
Safety of Bronchodilators in COPD 
Bronchodilators are the mainstay for symptomatic treatment of COPD due to their 
ability to relieve bronchial obstruction and airflow limitation, improve emptying of the 
lungs and reduce hyperinflation during rest and exercise.6,7 Bronchodilator treatments 
include beta-(β) 2-agonists, anticholinergics (AC), and methylxanthines, used alone or 
in combination. They are recommended as first-line agents useful to prevent or reduce 
symptoms as-needed or on a regular basis.7  Short-acting bronchodilators are typically 
used as rescue medication for immediate symptom relief, routinely in the early disease 
stages or in COPD patients with a low symptom burden whereas long-acting 
bronchodilators are used as regular maintenance therapy and are generally more 
effective and convenient.7 Combinations of bronchodilators may improve efficacy and 
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reduce risk of adverse effects rather than increasing the dose of a single agent.7 
Inhaled bronchodilators are preferred over oral preparations based on favorable 
efficacy and side effect profile.1 
Despite the benefits of bronchodilator agents in the treatment of COPD, patients 
may be at an increased risk of cardiovascular (CV) toxicity due to beta-adrenergic 
stimulation. Evidence on the safety of bronchodilator therapy in COPD is mixed. 
There have been reports on the relative safety of bronchodilator use in COPD 38 
whereas some researchers have found clinically significant higher risks in the 
incidence of cardiovascular events in patients on selected bronchodilator agents than 
control groups.8,11,12,39,40  
In 2003, Ferguson and coworkers38 evaluated the cardiovascular safety of 
salmeterol (a beta-2-agonist), in COPD patients by reviewing safety data from 
randomized, double-blind, parallel group, multiple-dose studies. Pooling results from 
7 clinical trials, the authors concluded that though both salmeterol and placebo groups 
had an increased incidence of adverse CV events with age, concurrent cardiovascular 
conditions, and treatment with antiarrhythmic/bradycardic agents, the incidence of 
cardiovascular events (8%), including cardiovascular deaths, was similar in both 
groups. 
However, a meta-analysis of randomized placebo-controlled trials of beta-2 
agonists in patients with obstructive airway disease (asthma and COPD) performed a 
year later, revealed opposite results.39 This study included longer duration trials in the 
analysis to evaluate both the short-term effect on heart rate and potassium 
concentrations, and the long-term outcome of adverse cardiovascular events. Adverse 
 9 
 
events included sinus and ventricular tachycardia, syncope, atrial fibrillation, 
congestive heart failure, myocardial infarction, cardiac arrest, or sudden death. From 
among 33 trials, the conclusion was that beta-2 agonist treatment significantly 
increased the risk for a cardiovascular event (relative risk RR 2.54; 95% CI, 1.59 to 
4.05) compared to placebo mainly because of the short term effects of tachycardia and 
hypokalemia. 
In 2008, Macie et al8 examined the relationship between use of inhaled 
respiratory drugs in people with chronic obstructive respiratory diseases and 
cardiovascular hospitalizations for 5years from 1996 through 2000 using the Manitoba 
Health Database. The nested case control study included exposure to beta agonists, 
anticholinergic (ipratropium bromide), and inhaled corticosteroids (ICS) and outcomes 
were first hospitalizations for supraventricular tachycardia, myocardial infarction, 
heart failure or stroke. The likelihood of a hospitalization for SVT, MI, and HF was 
significantly increased for those to whom beta agonists [OR 1.68, 95% CI 1.41–2.00], 
ipratropium [OR 1.48, 95% CI 1.29–1.70] but not ICS [OR 1.13, 95% CI 0.95–1.35] 
were dispensed within 60 days prior to the hospitalization. While it is likely that 
bronchodilator use was simply a marker of disease severity and this accounted for 
their association with cardiovascular disease, the authors note that ICS was not 
associated with these outcomes. The findings on specific drug interactions were that 
each case the receipt of cardiac drugs decreased the likelihood of hospitalizations 
associated with bronchodilator. For example, bronchodilators increased the risk of 
stroke in patients who were not taking cardiac drugs but did not increase the risk of 
arrhythmia in the presence of anti-arrhythmic agents. 
 10 
 
In 2012, another nested case-control study involving 6018 subjects with COPD 
from the Saskatchewan Cohort Study 9 found that the rate of arrhythmia was elevated 
with the new use of ipratropium, a short-acting anticholinergic agent (RR 2.4; 95% CI, 
1.4–4.0) and of long-acting β-agonists (RR, 4.5; 95% CI, 1.4–14.4). The researchers 
did not find an elevated risk with short-acting beta-2-agonists or methylxanthines and 
proceeded to ascertain the results in a larger patient pool. For the reassessment, the 
larger Quebec cohort of 76,661 subjects was analyzed.10 They found that the rate of 
arrhythmias increased with the new use of short-acting beta-2-agonists (RR, 1.27, 95% 
CI, 1.03–1.57) and long-acting beta-2-agonists (RR 1.47; 95% CI, 1.01–2.15), but not 
with ipratropium and methylxanthines. This slightly increased risk for short-acting 
beta-2 agonists and ipratropium corroborates evidence earlier obtained from the 
Manitoba Health Database.8 
Tiotropium, a once daily long-acting anticholinergic bronchodilator has also been 
reported for safety concerns regarding its use in the COPD patient population. In 2013, 
Singh et al 13 reported that an increased risk of all-cause mortality (RR 1.52; 95% CI, 
1.06–2.16) and CVD mortality (RR 2.05; 95% CI, 1.06–3.99) was associated with 
tiotropium use. Patients with known cardiac disease were also reported to have 
significantly high risk of dying from cardiac causes though the risk estimates largely 
varied among patients (RR 8.6; 95% CI, 1.1–67.2). 
In 2011, a retrospective cohort study of patients attending a Heart Failure (HF) 
Disease Management Programme was done by Bermingham and colleagues.11 The 
cohort size was 1294 patients (age 70.6+11.5 years) of whom 64% were male and 
22.2% were taking β2 agonists. The mean follow-up was 2.9+2.4 years. The study 
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intended to address gaps in literature that did not consider the influence of factors such 
as the dose, duration, or type of bronchodilator therapy (long acting vs. short acting) 
on outcomes. The primary endpoint was the effect of β2 agonist use compared with no 
β2 agonist use on mortality using unadjusted and adjusted Kaplan2Meier survival 
curves. Beta-agonist users were older, more likely to be male, to have smoked, to have 
chronic obstructive pulmonary disease (COPD) and asthma, and less likely to take 
beta-blockers. Unadjusted mortality rates for β2 agonist users were found to be 
significantly higher than non-β2 agonist users [hazard ratio (HR) 1.304, 95% CI 
1.030–1.652, P= 0.028]. Overall mortality rates were similar [HR 1.043, 95% CI 
(0.771–1.412), P=0.783] after adjusting for covariates like age, sex, beta-blocker use, 
co-morbidity, smoking, COPD, and differences in B-type natriuretic peptide (BNP). 
There was no influence of β2 agonist duration of use, dose, or type on outcome in 
fully adjusted models. 
The possible role of the mode of administration of bronchodilators in observed 
differences in treatment effects has also been explored. Available formulations include 
metered dose inhalers (MDI), dry powder inhalers (DPI) and soft mist inhalers (SMI). 
Using a retrospective study, Verhamme and colleagues12 investigated the risk of 
mortality between tiotropium Respimat (an SMI) vs Handihaler (DPI) and showed that 
the use of Respimat was associated with about 30% increased mortality (adjusted HR 
1.27; 95% CI, 1.03–1.57) compared with Handihaler and the association was strongest 
for cardiovascular /cerebrovascular death (adjusted HR 1.56, 95% CI 1.08-2.25).  The 
reason for this apparent elevated risk is not clear, though it may be related to rapid 
peak drug concentrations achieved after mist inhalation.40 
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The publications on safety of bronchodilators reveal the likelihood of different 
study designs to bias and confounding. Smoking status, non-respiratory drugs with 
known arrhythmogenic properties taken concomitantly may bias the study results. The 
adverse cardiovascular outcomes may reflect COPD severity or confounding by 
indication rather than an adverse effect of bronchodilator therapy. It is also possible 
that bronchodilators impose a larger relative risk in people with undiagnosed 
cardiovascular disease than in people with known disorders since bronchodilators did 
not increase the risk of arrhythmia in the presence of anti-arrhythmic agents. 
 
Utilization of Bronchodilators 
Although, long-term decline in lung function is irreversible in COPD, 
bronchodilators are recommended to reduce airflow obstruction, reduce the frequency 
of exacerbations, improve health status and decrease mortality.1  Therapy usually 
includes a short-acting bronchodilator or a long-acting bronchodilator (either a Beta-2-
agonist or an anticholinergic drug or a methylxanthine) or combination products for 
adequate clinical response and tolerance of side effects. 1     
A case-control study was conducted on the use of bronchodilators and 
arrhythmias in COPD in 2012.9  Out of 469 cases of arrhythmias, the proportion 
taking at least one short-acting β-agonist was 37.9%, long-acting β-agonists 1.9%, 
Ipratropium bromide 29.4% and Methylxanthine 10.2% compared to the controls 
where use was short-acting β-agonist was 35.2%, long-acting β-agonists 1.6%, 
Ipratropium bromide 22.2% and Methylxanthine 8.7%. The percentage of β-blocker 
users in the study sample was 11.6% and overall cardiovascular medication prescribed 
 13 
 
is 22.4%. Groenwold and colleagues described the characteristics of a cohort of 3376 
COPD/ asthma patients that were beta-agonist users and non-users.41 47.5% were 
female, 16.7% of the medication users had diagnosed cardiovascular disease, 29.1% 
utilized beta-agonist and 16.7% had prescriptions for anticholinergic drugs.  
In addition to the relationship between bronchodilators and cardiovascular disease 
in COPD, evidence that medication prescribing may differ by patient demographic 
characteristics exists. Treatment differences by sex in the utilization of bronchodilators 
and other COPD medications were investigated in a cross-sectional analysis based on 
10 year data from two national datasets - National Ambulatory Medical Care Survey 
(NAMCS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS).42   
Women had a consistently higher proportion of visits with COPD medication 
prescriptions than visits by men. The frequency of COPD medications prescribed to 
women decreased by 7% (from 73% to 67%) during the study period (1995-2004). 
The average number of COPD drug mentions per visit decreased for both women and 
men and trends were significantly different between men and women (P < 0.001). 
Prescription of methylxanthines decreased in visits by women and men, whereas 
prescription of anticholinergics increased continuously in the recent years. 
Certainly, the high prevalence of COPD and cardiovascular disease warrant 
further study of prescribing patterns in COPD patients with cardiac conditions. Thus, 
the purpose of the present study is to determine whether COPD patients in ambulatory 
care in the United States have a lower likelihood of being prescribed bronchodilators if 
they have concurrent CVD compared to those without CVD.  
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CHAPTER 3 
 
METHODOLOGY 
 
Data Source 
The 2010 National Ambulatory Medical Care Survey (NAMCS) 43 was the source 
of data used to assess COPD patient visits. The NAMCS is designed to collect data on 
outpatient visits from non-federally employed office-based physicians in the United 
States and it is conducted annually by the National Center for Health Statistics 
(NCHS), a division of the Centers for Disease Control and Prevention (CDC). The 
survey employs multistage probability sampling design to generate unbiased national 
estimates. These data are weighted to be nationally representative of outpatient doctor 
visits throughout the United States. 
The unit of data collection is the visit or encounter not patient-level. NAMCS 
data contains variables on reason for visit, diagnoses, diagnostic/screening services 
provided, medication therapy, demographic characteristics of patients, specialty of 
physician seen, and certain characteristics of the facility, such as geographic region 
and metropolitan status for a randomized sample of patient visits during a randomly 
selected 1-week time period. The NAMCS has gained enormous popularity as a choice 
dataset to assess national trends in ambulatory medical care utilization and examine 
concordance of prescribing patterns with evidence-based treatment guidelines. 
Therefore, we consider the dataset suitable for this analysis. The 2010 NAMCS data 
were used because they were the most recently available.   
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The Institutional Review Board of the University of Rhode Island recognizes that 
studies using de-identified, publicly available data do not constitute human subjects 
research and granted exempt status for this study. 
 
Analytic sample 
The study population consisted of patients aged 40 years and over, who had visits 
where chronic obstructive pulmonary disease (COPD) was diagnosed. A patient visit 
was included if the COPD International Classification of Diseases, 9th revision, 
Clinical Modification ICD-9-CM codes 491, 492 and 496 were listed as 1 of 3 
diagnoses for that visit. COPD visits were compared to number of ‘Yes’ responses to 
the question “Does the patient now have COPD (Yes/No)” captured on the patient 
record form. Figure 1 depicts the inclusion and exclusion criteria. 
Further stratification of COPD sub-groups was done by presence or absence of 
concurrent diagnosis of cardiovascular conditions of interest.  Based on previous 
studies, the following cardiovascular diseases were selected: myocardial infarction, 
angina, coronary artery disease, cardiac arrhythmias (including tachycardia, atrial 
fibrillation, and cardiac arrest), and congestive heart failure. The ICD-9 diagnosis 
codes are presented in Table 2. 
 
Variables Specification 
 The dependent variable is defined as the prescription of a bronchodilator at a 
visit (Rx =1 or 0). New or continued bronchodilators recorded in any of the 32 
therapeutic class fields were identified using the therapeutic class codes extracted from 
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NCHS’s Ambulatory Care Drug Database. Table 3 shows the relevant drug codes. The 
drug visits strategy was used instead of drug mentions because we are interested in a 
binary response per visit (any bronchodilator treatment Rx=1 vs no bronchodilator 
treatment Rx=0) not the total number of times bronchodilators are mentioned in the 
entire study population, which was more than one bronchodilator medication for each 
ambulatory medical care visit, on the average.  
Bronchodilator users were stratified into 4 therapeutic categories (beta-(β) 2-
agonists, anticholinergics (AC), methylxanthines and combination bronchodilators) to 
estimate the proportion of users in each subclass and compare bronchodilator therapy 
across CVD exposure variable and other visit characteristics. Table 3 outlines the 
commercially available bronchodilator medications according to pharmacological 
classes. It should be noted that all bronchodilator-containing drugs whether single 
agents or in combination with corticosteroids were included in the outcome variable 
definition. 
The independent variable of interest is CVD status (Dx =1 or No Dx=0). Age was 
modeled as a continuous variable. All other explanatory variables (confounders/effect 
modifiers): tobacco smoking, physician specialty, type of healthcare insurance, use of 
inhaled corticosteroids, cardiac medications (antiarrhythmic and beta-blockers) and 
asthma were measured as categorical variables.   
Some study covariates had to be re-coded by removing unknown or missing 
responses, collapsing/combining categories and dummy coding. Categorical 
independent variables were dummy coded as follows: Race/ethnicity was recoded into 
4 groups as Non-Hispanic White (0), Non-Hispanic Black (1), Hispanic (2) and Non-
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Hispanic Other (3). Tobacco use was recoded into Non-current (0) and Current (1).  
Use of selected medications including inhaled corticosteroids, antiarrhythmic drugs 
and beta-blockers were recoded into No (0) and Yes (1) values. Health insurance 
coverage was collapsed into 4 categories and dummy coded - Medicare (0), Private 
insurance (1), Medicaid (2) and Other (3). The last group combined other sources of 
payment like self-pay, worker’s compensation, no Charge/Charity. Similarly, 
physician specialty initially presented as 15 groups was collapsed into 4 groups since 
some specialties had no or very few COPD patient visit to have meaningful 
interpretation. General/Family Practice, Internal Medicine, Cardiology and Other were 
the 4 dummy variables created. 
 
Parametric Assessment 
A parametric assessment was done to determine if continuous independent 
variables satisfied the assumption of linearity in the logit. Age was the only 
continuous variable and was categorized into 3 groups 40-54, 55-74 and 75 & over for 
the univariate logistic regression analysis. In the results obtained, the Odds Ratios 
followed a positive linear relationship with bronchodilator prescription across the 
different age groups (Appendix - Figure 3) and implies it can be coded as either a 
continuous or categorical variable. Age was modeled as a continuous variable for the 
purpose of this study. 
 
Descriptive Statistics and Modeling Strategy 
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Descriptive statistics, univariate and multivariate techniques were used. All 
analyses were performed on weighted data as recommended by the NCHS. The patient 
visit weighting, as provided, uses the most recently available census data to provide a 
stratified representation of the nation’s patient population. All statistical analyses were 
done using SAS version 9.3 and the results report weighted information. 
For descriptive analysis, the means (with standard error) and proportions of 
demographic, clinical and medication utilization characteristics for the study 
population were calculated. Rates of drug visits were computed for the sub-categories 
of bronchodilator medications. Bivariate associations between the dependent variable 
(prescription of one or more bronchodilators) and each independent variable were 
separately estimated using univariate logistic regression to obtain unadjusted Odds 
Ratios and 95% confidence intervals. This will enable inferences to be deduced about 
the true population parameter lies between the confidence limits with 95% certainty. 
Confounding and interaction were assessed given that they may bias the 
relationship between CVD morbidity and treatment with bronchodilators. Two 
multivariate logistic regression (LR) models were developed - one containing 
interaction terms plus confounding variables and the other without interaction 
(confounders only). First of all, interaction was tested by applying the hierarchy 
principle to combinations of variables. This implies that if certain interaction terms are 
significant, all lower order components of such terms cannot be deleted and will 
remain in any further models considered. Two-way interaction analysis was performed 
for the following pairs of variables: CVD and gender, CVD and beta-blockers, CVD 
and asthma. Here, the Odds Ratios of prescribing a bronchodilator for COPD in a 
 19 
 
CVD patient is described in terms of the modifying variable, either gender, beta-
blockers or asthma.  The multivariate logistic regression (LR) model without 
interaction terms was developed. 
Both multivariate models included a number of confounders - Age, gender, race, 
insurance coverage, asthma, concomitant antiarrhythmic and beta-blocker use, and 
physician specialty. Therefore, the multiple regression analysis presented adjusted 
models and allowed us to quantify the true association between concurrent COPD-
CVD morbidity and the probability of receiving a bronchodilator prescription, while 
controlling for the effects of other explanatory variables.  
 
Model fit 
The next step in the model building procedure was to verify whether or not the 
model fitted the data well. Hosmer and Lemeshow goodness-of-fit test and a 
likelihood ratio test were conducted on the two multivariate logistic models - full 
model with interaction and reduced model without interaction. A final model was 
selected based on the adequacy of the fit. 
In interpreting the results of the likelihood of prescribing a bronchodilator for 
COPD visit of a patient with cardiovascular comorbidity, the Adjusted Odds Ratios 
derived from the selected multivariate logistic regression model were used. The 95% 
confidence intervals were also calculated for each Odds Ratio. 
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CHAPTER 4 
 
FINDINGS 
 
Study Sample Characteristics 
An estimated 13,799,072 visits of patients above 40 years had a diagnosis of 
COPD occurred in 2010 in the US. This is approximately 1.4% of 1billion annual 
office visits. Missing or unknown data were removed leaving 11,627,061 visits in the 
analytic sample (Table 4). 
The majority of the population (57%) was male, between 55 and 74 years (mean 
age, 69 years). Over 80% were Non-Hispanic White and only 8.3% had the cardiac 
comorbidities of interest. In terms of the dependent variable, 55.5% of the COPD 
visits had a bronchodilator prescription. Source of payment for most visits was 
reported to be Medicare (67.5%) which is consistent with the average age ≥ 65 years 
eligible for Medicare benefits. 14.4% had a concurrent diagnosis of asthma showing 
that some patients may be suffering from the asthma-COPD overlap syndrome. A 
small proportion of visits received a prescription for inhaled corticosteroids. 
Concomitant use of cardiac medications like anti-arrhythmic agents and beta-blockers 
occurred in 14.3% and 23.4%. Cardiologists had a lower percentage of the office visits 
compared to Internal Medicine doctors (22.5%), Family physicians (29.4%) and other 
specialties (44%). 
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Univariate Logistic Regression 
The univariate logistic regression analysis performed indicated that most of the 
independent variables were significantly associated with the dependent variable (Table 
5). Of the 11,672,061 COPD visits, 55.5% had a bronchodilator (BD) prescribed. CVD 
visits had lesser odds (OR = 0.35, 95% CI 0.31 - 0.4) than non-CVD visits of receiving 
a prescription for a bronchodilator. Females had a lower chance of being prescribed a 
bronchodilator compared to males OR= 0.51 95%CI 0.47 - 0.55). In terms of patient 
ethnicity, Hispanics and non-Hispanics blacks were about 24% and 78% less likely to 
have a bronchodilator medication than Non-Hispanic Whites because they had lower 
OR of 0.76 (95%CI 0.62, 0.92) and 0.22 (95%CI 0.2, 0.26) respectively. There was no 
significant treatment difference between non-Hispanic whites and non-Hispanics 
persons that were neither white nor black (OR = 0.94, 95% CI 0.74 -1.19). 
The effect of age on the likelihood of bronchodilator use was significant in the 
univariate regression analysis (OR = 1.01, 95% CI 1.01 - 1.02 p= <0.0001). Odds Ratio 
of 1.01 implies that the chance of being prescribed the medication increases by 10% 
with every 10 years of increasing age. Surprisingly, current smokers were half as likely 
to be prescribed one or more bronchodilators compared to those who did not currently 
smoke (OR = 0.55 95% CI 0.51 - 0.59). The most likely reason is that those who 
eventually developed COPD and were taking medications may have quit smoking and 
be in the ‘not current’ category. Again, the implication of the broad categorization of 
the tobacco use variable into ‘Current’ and ‘Not current’ smokers is that it excludes 
smoking behaviors like ex-smokers, never smokers, heavy or light smokers and we 
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cannot compare treatment differences. There was a strong association between asthma 
and bronchodilator utilization as revealed by the odds ratio of 4.64, 95% CI 4.07 - 5.3. 
The use of inhaled corticosteroids appears to increase the chance that patient is 
also taking a bronchodilator (OR=2.84, 95% CI 2.23 - 3.63) while beta-blocker 
utilization decreased the probability of concomitant bronchodilator treatment 
(OR=0.88, 95% CI 0.80 - 0.95). Antiarrhythmic drugs were not associated with 
prevalent BD use (OR = 1.02, 95% CI 0.92 - 1.13). 
Physician specialty and type of insurance were associated with increased odds of 
receiving a bronchodilator during a doctor visit (p-value < 0.001). A patient who had 
private insurance (OR=1.12, 95%CI 1.02 - 1.21) or was seen by a cardiologist (OR= 
1.32, 95%CI 1.09 - 1.59) or other specialty (OR=2.13, 95%CI 1.95 - 2.33) was more 
likely to get a BD prescription compared to those in the reference category who had 
Medicare coverage or were seen by a family doctor or internal medicine specialist 
(OR=1.00). Medicaid enrollees did not differ in their treatment with bronchodilators for 
COPD diagnosis (OR=1.09, 95%CI 0.91 -1.31).  
 
Multivariate Logistic Regression 
Two multivariate logistic regression (LR) models were developed - one containing 
interaction terms, exposure and other independent variables and the other without 
interaction (exposure plus independent variables only).   
In the interaction model, the effects were significant between CVD and each of 
three possible modifying variables tested - gender, beta blockers (BB) and asthma since 
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all p-values < 0.05. All three modifiers and their product terms with CVD were retained 
in the model according to the hierarchy principle.  
The reduced model without interaction terms contained the exposure variable 
(CVD), and potential confounding variables yielded the results in Table 8. A likelihood 
ratio test was conducted based on the null hypothesis of ‘no interaction’ versus 
‘interaction’ as alternative hypothesis. The test statistic was 134.4, p-value < 0.0001 
produced evidence that the ‘interaction’ model is a significantly better fitting model. 
Therefore, the interaction model was selected as the best model and this final choice 
guided the interpretation of the parameter estimates and odds ratios. Table 7 displays 
the Odds Ratio for the modifying effect of gender, asthma and β-blockers on the 
association between CVD and bronchodilator prescribing in COPD. 
For effect modification by gender, CVD had a greater effect on bronchodilator 
prescribing compared to the non-CVD group in females with neither asthma nor beta-
blocker medication. OR=0.06, 95%CI 0.04-0.09 implies a 94% reduction in the 
probability of receiving bronchodilator. In males with no asthma and no beta-blocker 
utilization, the effect of CVD was 68% since OR=0.32, 95%CI 0.25-0.40. The highest 
difference in the odds of bronchodilator use between CVD and non-CVD groups was 
observed in females who had asthma and did not use beta-blockers (OR=0.03, 95%CI 
0.02-0.06). Thus, this patient group had the least chance of taking bronchodilators. 
CVD was not associated with bronchodilator prescribing in male beta-blocker 
users, regardless of asthma status (for male, BB users with asthma OR=0.62 95%CI 
0.33-1.16; for male BB users without asthma OR=1.11 95%CI 0.82 - 1.51). Therefore, 
cardiovascular disease did not affect the outcome in this category of patients. On the 
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contrary, CVD female beta-blocker users without asthma had 79% less probability of 
receiving a bronchodilator than similar patients without CVD. 
The effect of cardiovascular disease was also modified by concomitant asthma to 
different degrees. CVD asthma patients who were males and not taking BB were only 
17% as likely to be prescribed bronchodilators compared to those without CVD, that is, 
83% less chance of receiving the drug. The effect of CVD was stronger for female 
asthma patients taking BBs with 89% lower likelihood, and strongest for female asthma 
patients who did not use BB (97% lower likelihood). 
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CHAPTER 5 
 
DISCUSSION 
 
Our study revealed that β-agonists were the most frequently prescribed class of 
bronchodilators and were prescribed at 56.4% of COPD visits. This fact supports 
previous studies.44 We conducted this cross-sectional study to determine whether 
prescribing rates of bronchodilators in COPD patients were different in cardiovascular 
comorbidities and if so, to what extent patient characteristics modified the prescribing 
pattern in ambulatory care in the United States.   
We found that most COPD patients, who had been diagnosed with cardiovascular 
disease, were prescribed bronchodilators less frequently than were those who had 
COPD without cardiovascular diagnosis, but that this relationship was modified by 
patient characteristics.  This pattern was more evident for females, whereas males had 
less pronounced differences between CVD and non-CVD groups.  Our finding was 
consistent with literature on treatment differences in bronchodilator utilization for 
comorbid groups. 45   
There were significant interactions between cardiovascular disease and gender, β-
blocker and asthma, shown in Table 7. The presence of cardiovascular diagnosis 
significantly decreased the likelihood of bronchodilator prescription by 97% for 
females who were not taking beta-blockers but had asthma (OR=0.03, 95% CI 0.02-
0.06). Males with similar characteristics had 83% reduced odds of taking 
bronchodilators. This was not entirely suspected as a previous cross-sectional study by 
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Suh et al based on 10 years data from the NAMCS and hospital files (NHAMCS) 42  
found that women had a consistently higher proportion of visits with COPD medication 
prescriptions than visits by men. 
No significant difference in bronchodilator utilization between CVD and non-CVD 
groups was observed with the use of beta-blockers in males who were either asthma 
(OR=0.62 95% CI 0.33-1.16) or non-asthma patients (OR=1.11 95%CI 0.82-1.51). A 
possible explanation may be that the concurrent use of beta-blockers for cardiac 
conditions and bronchodilators (which are majorly beta-agonists) in patients with 
multiple morbidities, leads to opposing pharmacological activity due to interaction 
between these medications. Other studies have found that the effects of β-agonists may 
be diminished by β-blockers and vice-versa.46  In the Cooperative Cardiovascular 
Project47, β-blocker use was not associated with lower mortality among patients 
receiving concurrent beta-agonists. Subjects enrolled in the Veterans Administration’s 
ACQUIP trial who received both beta-blockers and beta-agonists had no increase in 
risk of acute coronary syndromes.48  However, we did not observe this nullifying effect 
among females with comparable characteristics. The effect of CVD on bronchodilator 
prescribing in females taking beta-blockers with coexisting asthma was about 79% less 
than those without CVD (OR=0.21 95%CI 0.14 - 0.30). These results point to the fact 
that the effect of CVD on prescribing differs between males and females who 
concurrently use beta-blockers and bronchodilators (mainly beta-agonists) and suggest 
more conservative prescribing practices for females than for males.   
 
 
 27 
 
Strengths and Limitations 
One of the strengths of the current study is the dataset. The NAMCS provides a 
national perspective on drug utilization in ambulatory medical care. We included 
patients with COPD diagnosis, race and ethnicity data, sources of payment, all regions 
and physician categories across the United States. Standard ICD-(-CM coding used for 
all the diagnoses aided identification of the COPD and cardiovascular conditions of 
interest. Apart from the ICD-9 codes, the survey included separate physician-defined 
variables for chronic conditions like COPD, Congestive heart failure, Ischemic heart 
disease. For example, the questions on the patient record form came in form of “Does 
the patient now have COPD (Yes/No)”. We could compare responses from both 
approaches to increase the reliability of patients’ diagnosis. The Ambulatory Drug 
database had specific drug codes for each therapeutic class which were employed for 
easy analysis of medication utilization for bronchodilators, cardiovascular drugs and 
their therapeutic subcategories. The inclusion of these details helped to evaluate 
differences in the use of bronchodilators across patient characteristics. 
This study has limitations related to the study design and datasource. Because of 
the cross-sectional nature of the study design, the disease diagnosis and use of 
medications prescribed were collected at a single point in time, precluding the 
researcher from establishing the temporal relationship between onset of cardiovascular 
disease and initiation of bronchodilator treatment. 
Bronchodilator prescriptions were assumed to be directly indicated for COPD 
treatment which may not be accurate. The NAMCS data has a comprehensive list of 
medications and diagnosis codes documented for each patient encounter but since there 
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is no clear match between the prescribed medications and ICD-9 diagnosis codes, we 
could not verify the specific diagnosis for which bronchodilators are being prescribed.  
Future improvements to the survey design to establish a link between these disease 
condition and medications prescribed would be helpful to researchers. The dataset did 
not contain specific information that would indicate that patients may have a 
contraindication or past drug-related adverse event, thereby preventing the use of one 
or more bronchodilator medication. 
Another limitation is the type of drug formulation. 17.4% of the prescribed 
products per visit were fixed combinations of different classes of bronchodilators or a 
bronchodilator in addition to an inhaled corticosteroid. However, we categorized and 
assessed them like any other bronchodilator in the study because evidence suggests 
inhaled corticosteroid present less cardiovascular risk unlike oral corticosteroids that 
may cause sodium and fluid retention leading to elevated blood pressure and adverse 
cardiovascular effects.49,50 Combination regimens are substantially utilized in COPD 
due to the increased effectiveness, reduced burden of medication use and increased 
adherence that can potentially achieved with this agents. Therefore, all bronchodilator-
containing drugs whether single agents or in combination with corticosteroids were 
included in the definition of the outcome variable. 
We considered including disease severity measures as covariates in this study but 
were unable to because the cross-sectional data did not contain clinical outcomes or 
follow-up information. Prescribing practices often differ from provider to provider and 
it may be worth investigating predictors of bronchodilator prescribing among 
physicians. Future research should attempt documenting the physician characteristics 
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influencing bronchodilator prescribing for COPD patients. The outcome of this type of 
analysis can provide inputs for shaping integrated disease management programs for 
concurrent COPD and CVD conditions. 
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CHAPTER 6 
 
CONCLUSION 
 
Despite considerable research interest in the potential risk of cardiac events 
associated with use of bronchodilators in COPD patients, few studies have analyzed 
the real-world prescribing rates of this highly utilized COPD therapy in 
cardiovascular disease. This study presents a unique national perspective to 
understand the effect of CVD on prescribing practices of bronchodilators in the 
United States. 
Concurrent CVD diagnosis is a significant factor for reducing the probability of 
prescribing bronchodilators for COPD and the odds of prescribing were further 
decreased due to differences in gender, asthma and beta-blocker use. CVD patients 
who were female, not taking beta-blockers and not having concomitant asthma were 
94% less likely to be taking bronchodilators compared the non-CVD females with 
same characteristics. On the other hand, males not taking beta-blockers and not 
having concomitant asthma had 68% lower probability when CVD coexisted with 
COPD. Female CVD patients taking beta-blockers and not living with asthma had 
only 20% chance of being a bronchodilator user than those without CVD. It is 
noteworthy that the general pattern observed in these national data is consistent with 
treatment guidelines that advise using bronchodilators with caution in the comorbid 
COPD-CVD patient population, however cardiovascular disease did not affect the 
utilization of bronchodilators in males taking beta-blockers. 
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Our findings provide evidence that most patients with COPD and CVD are less likely 
to be prescribed bronchodilators, with the exception of males who were also 
prescribed beta-blockers.  Thus this study highlights a specific patient subgroup for 
whom the guidelines are less likely to be observed.  
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Table 1: Selected Information on the 2010 NAMCS Data and Analytic Sample 
 
Survey Item Data  Result 
Unweighted number of office visits recorded by participating 
physicians  2010 
NAMCS 
31, 229 
Weighted number of representative ambulatory-based medical 
care office visits in the United States 1,008,802,005 
Unweighted number of office visit records for COPD patients 
40 years and over, without missing/unknown values Analytic 
sample 
263 
Weighted number of representative COPD office visits for 
patients 40+years in the United States 11,627,061 
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Table 2: ICD-9-CM diagnosis codes for COPD and cardiovascular diseases 
 
Description of Diagnosis 
Diagnosis 
code 
Study 
variable 
Chronic bronchitis 491.xx COPD 
Emphysema 492.xx COPD 
Chronic airway obstruction 496.xx COPD 
Acute myocardial infarction 410.xx CVD 
Angina pectoris 413.xx CVD 
Coronary artery disease 414.xx CVD 
Cardiac arrhythmias (including tachycardia, atrial 
fibrillation) 427.xx CVD 
Congestive heart failure 428.xx CVD 
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Table 3: List of NAMCS 2010 Pharmacologic classes and codes of bronchodilator 
medications  
 
Drug 
therapeutic 
category 
Level 2 
Drug 
therapeutic 
category 
Level 3 
Sub-class Generic 
names 
Brand 
names 
available in 
2010 
Bronchodilators 
(code 125) 
Beta-2-agonists  
(code 180) 
Short-acting  
Beta-2-agonists 
(SABA) 
Albuterol, 
levalbuterol, 
metaprotenerol 
Ventolin, 
Proair, 
Proventil, 
VoSpire, 
Xopenex, 
Long-acting  
Beta-2-agonists 
(LABA) 
Arformoterol, 
formoterol, 
salmeterol,  
Brovana,  
Foradil, 
Perforomist, 
Serevent, 
Anticholinergics  
(code 299) 
Short-acting 
Anticholinergics  
Ipratropium Atrovent 
Long-acting 
Anticholinergics  
Aclidinium, 
tiotropium 
Tudorza 
Pressair, 
Spiriva 
Methylxanthines 
(code 126) Methylxanthines 
Aminophylline
, dyphylline, 
theophylline 
Lufyllin,  
Jay-Phyl, 
Theo-24, 
Elixophyllin, 
Uniphyl, 
Combination 
bronchodilators 
(code 181) 
Beta-2-agonists 
plus 
anticholinergic 
Albuterol/iprat
ropium,  
Combivent, 
Beta-2-agonists 
plus 
corticosteroid 
Salmeterol/Flut
icasone 
Advair 
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Table 4: Demographic and Clinical characteristics of COPD visits (N=11,627,061) 
Characteristic 
Weighted Estimates ┼ 
No. (‘000s) % 
Age Mean age * 69.2 (0.9)  
 
40 – 54 1331 11.4 
 
55 – 74  6296 54.1 
 
≥ 75 4000 34.4 
Gender Female 4999 43.0 
 
Male 6628 57.0 
Race/ethnicity Non-Hispanic White 9545 82.1 
 
Non-Hispanic Black 1376 11.8 
 
Hispanic 418 3.6 
 
Non-Hispanic Other 289 2.5 
Region Northeast 1556 13.4 
 
Midwest 1928 16.6 
 
South 6097 52.4 
 
West 2046 17.6 
Tobacco Use  Current 7392 63.6 
 
Not current 4235 36.4 
Cardiovascular disease CVD** Yes 960 8.3 
 
No 10667 91.7 
Bronchodilator prescription Yes 6456 55.5 
 
No 5171 44.5 
Type of Bronchodilator 
prescribed 
Beta-2- agonist 3638 56.4 
Anticholinergics 1604 24.8 
 
Methylxanthines 89 1.4 
 
Combination bronchodilators 1126 17.4 
Concomitant Asthma Yes 1677 14.4 
 
No 9950 85.6 
Inhaled corticosteroid use Yes 379 3.3 
 
No 11248 96.7 
Antiarrhythmic drugs Yes 1658 14.3 
 
No 9969 85.7 
Beta-blockers Yes 2726 23.4 
 
No 8901 76.6 
Payment Source Private Insurance 2996 25.8 
 
Medicare 7848 67.5 
 
Medicaid 505 4.3 
 
Other 277 2.4 
Physician specialty General/Family Practice 3424 29.4 
 
Internal Medicine 2620 22.5 
 
Cardiology  489 4.2 
 
Other specialty 5094 44 
*    Mean age and standard error in years 
**  CVD includes myocardial infarction (0.05%), angina (0.3%), coronary artery disease (5.15%), cardiac 
arrhythmias 2.0% (including tachycardia, atrial fibrillation), congestive heart failure (0.7%) 
┼  Weighted values represent the sample adjusted to represent national visit characteristics 
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Table 5: Utilization of bronchodilator by CVD status 
 
Type of 
bronchodilator (Yes) 
% 
CVD 
% 
No CVD 
p-value 
Beta-2- agonist 5.1 94.9 
< 0.0001 
Anticholinergics 6.9 93.1 
Methylxanthines 0 100 
Combination 
bronchodilators 1.1 98.9 
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Table 6: Univariate Logistic Regression Analysis of NAMCS 2010 COPD visits of 
patients ≥ 40years with bronchodilator prescription by covariates 
Characteristic   
% of COPD 
visits receiving  
Bronchodilator 
prescription 
Unadjusted 
Odds Ratio 
(95% CI) 
 
  
 
 
 
Cardiovascular disease Yes 32.3 0.35 (0.31, 0.4)  <0.0001 
 
No 57.6 1.00 (reference)   
Gender Female 46.1 0.51 (0.47,0.55)  <0.0001 
 
Male 62.7 1.00 (reference)   
Age 
 
55.5 1.01 (1.01,1.02)   
Race/ethnicity Non-Hispanic White 59.9 1.00 (reference)  <0.0001 
 
Non-Hispanic Black 25.1 0.22 (0.2,0.26)   
 
Hispanic 53.1 0.76 (0.62,0.92)   
 
Non-Hispanic Other 58.4 0.94 (0.74,1.19)   
Tobacco Use  Current 46.1 0.55 (0.51,0.59)  <0.0001 
 
Not current 60.9 1.00 (reference)   
Patients with Asthma Yes 82.8 4.64 (4.07,5.3)  <0.0001 
 
No 50.9 1.00 (reference)   
Inhaled corticosteroid use Yes 77.5 2.84 (2.23,3.63)  <0.0001 
 
No 54.8 1.00 (reference)   
Antiarrhythmic drugs Yes 55.9 1.02 (0.92,1.13)  0.7159 
 
No 55.5 1.00 (reference)   
Beta blockers Yes 53.0 0.88 (0.8,0.95)  0.0023 
 
No 56.3 1.00 (reference)   
Health Insurance type Private Insurance 57.6 1.12 (1.02,1.21)   
 
Medicare 55.0 1.00 (reference)  0.0005 
 
Medicaid 57.1 1.09 (0.91,1.31)   
 
Other 45.6 0.69 (0.54,0.88)   
Physician specialty 
General/Family 
Practice 
48.8 1.00 (reference)  <0.0001 
 Internal Medicine 42.1 0.76 (0.69,0.85)   
 Cardiology  55.6 1.32 (1.09,1.59)   
 Other specialty 67.0 2.13 (1.95,2.33)   
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Table 7: Modification of the effect of cardiovascular disease comorbidity on 
bronchodilator prescription in COPD 
 
Exposure 
(CVD) 
Effect modifier (s) * 
Adjusted 
Odds 
Ratio 
95% 
confidence 
limits 
Effect measure 
modification ** 
Yes Male, no Asthma, no β-blocker 0.32 0.25 - 0.40 68% 
No Male, no Asthma, no β-blocker 1.00 reference  
  
Yes Male, Asthma, no β-blocker 0.17 0.10 - 0.31 83% 
No Male, Asthma, no β-blocker 1.00 reference  
  
Yes Male, no Asthma, β-blocker 1.11 0.82 - 1.51 None 
No Male, no Asthma, β-blocker 1.00 reference  
  
Yes Male, Asthma, β-blocker 0.62 0.33 - 1.16 None 
No Male, Asthma, β-blocker 1.00 reference  
  
Yes Female, no Asthma, no β-blocker 0.06 0.04 -0.09 94% 
No Female, no Asthma, no β-blocker 1.00 reference  
  
Yes Female, Asthma, no β-blocker 0.03 0.02 - 0.06 97% 
No Female, Asthma, no β-blocker 1.00 reference  
  
Yes Female, no Asthma, β-blocker 0.21 0.14 - 0.30 79% 
No Female, no Asthma, β-blocker 1.00 reference  
  
Yes Female, Asthma, β-blocker 0.11 0.07 - 0.19 89% 
No Female, Asthma, β-blocker 1.00 reference  
 
*   Effect modifiers are gender, asthma and β-blockers 
** Effect measure modification was calculated by the difference between the odds in the CVD 
group and the non-CVD comparison group, on a percent-scale 
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Table 8: Multivariate Logistic Regression Analysis of bronchodilator 
prescription in COPD without effect modification 
 
Characteristic Factor 
Adjusted Odds Ratio  
(95% CI) 
Main effects   
CVD Yes 0.30 (0.25 - 0.35) 
 No 1.00 (reference) 
Gender Female 0.50 (0.46 - 0.55) 
 Male 1.00 (reference) 
Beta blockers Yes 0.90 (0.82 - 1.00) 
 No 1.00 (reference) 
Asthma Yes 4.85 (4.17 - 5.63) 
 No 1.00 (reference) 
Race/ethnicity Non-Hispanic White 1.00 (reference) 
 Non-Hispanic Black 0.24 (0.21 - 0.28) 
 Hispanic 0.39 (0.32 - 0.49) 
 Non-Hispanic Other 1.49 (1.15 - 1.93) 
Tobacco Use  Current 0.55 (0.50 - 0.61) 
 Not current 1.00 (reference) 
Inhaled corticosteroid use Yes 1.52 (1.15 - 2.00) 
 No 1.00 (reference) 
Antiarrhythmic drugs Yes 1.71 (1.50 - 1.94) 
 No 1.00 (reference) 
Health Insurance type Private Insurance 1.47 (1.32 - 1.62) 
 Medicare 1.00 (reference) 
 Medicaid 1.68 (1.34 - 2.10) 
 Other 1.15 (0.85 - 1.55) 
Physician specialty General/Family Practice 1.00 (reference) 
 Internal Medicine 0.72 (0.64 - 0.81) 
 Cardiology  1.94 (1.56 - 2.43) 
 Other specialty 2.00 (1.81 - 2.22) 
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Figure 1: Flow Chart of application of study eligibility criteria 
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Figure 2: Two-way contingency table for Primary IV and DV 
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Figure 3: Parametric Assessment of Continuous Variables 
 
 
 
Reference class= agecat2 
Effect 
Age 
category 
Mid-point % Frequency Odds Ratio 
agecat 1 40 - 54 47.5 11.4 0.709 
agecat 2 55 - 74 65 54.1 1.00 
agecat 3 75 & over 89.5 
 
34.4 1.378 
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